Bayer is moving its US glyphosate business into a standalone subsidiary called Ruveon. The spin‑off seeks to limit Bayer’s direct exposure to costly glyphosate litigation and could affect the valuation of its crop science segment. Bayer AG,Ruveon (new subsidiary),U.S. plaintiffs in glyphosate lawsuits,Regulators such as the EPA and EU agencies Shareholder vote on the spin‑off expected in the coming quarter,Continued litigation against Ruveon,Market reaction to Bayer’s share price,Regulatory review of the separation structure Bayer has announced the transfer of its US glyphosate operations to a newly created subsidiary named Ruveon. The move is presented as a way to separate the herbicide business from the rest of the group amid thousands of U.S. lawsuits alleging cancer risks from the weedkiller. By isolating the glyphosate assets, Bayer aims to protect its broader operations while the new company assumes the associated liabilities.
INTELLIGENCE
Social Pulse
AI estimate · not scraped